What This Bill Does · Plain English
Summary · Congress.gov
Biosimilar Red Tape Elimination Act This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products. A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law. Further, the first biosimilar deemed interchangeable with a given reference product is awarded a period of marketing exclusivity. The bill eliminates additional requirements for demonstrating interchangeability so that all licensed biosimilars are deemed interchangeable with their reference products. (Draft guidance released by the FDA in 2024 proposed to make some of these interchangeability requirements optional, including studies related to the safety of switching between use of the biosimilar and reference product. It has not been finalized.) This change takes effect 60 days after the bill is enacted, and previously licensed biosimilars must be deemed interchangeable with their reference products on that date. However, the bill preserves the exclusivity period for first interchangeable biosimilars licensed before the bill’s enactment. For example, if a new biosimilar licensed after
Action Timeline
2026-07-27
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
2026-07-27
Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
2026-07-27
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
2026-06-17
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
2025-06-04
Introduced in Senate
2025-06-04
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Frequently Asked Questions
Did S.1954 pass?
S.1954 is still alive. Current stage: FLOOR. Pass likelihood: pending.
What does S.1954 do?
Biosimilar Red Tape Elimination Act This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products. A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law.…
Who sponsored S.1954?
S.1954 was sponsored by Mike Lee (R-Utah).
Full Bill Text
Full text not yet indexed for this bill. Check Congress.gov for the official text.
Loading intelligence layer…